Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Adds Warrants That Potentially Increase Gross Size of Offering

New York, NY, 2015-09-28 08:30 CEST (GLOBE NEWSWIRE) --  

Oasmia will issue to each investor in its proposed offering of American Depositary Shares, or ADSs, one warrant to purchase such ADSs for each two ADSs sold in the offering.  The warrants will be exercisable immediately at an exercise price of 125% of the offering price of the ADSs and will expire four (4) years from the date of issuance. Assuming closing of the offering, including the sale of warrants therein, the gross proceeds raised in the offering would increase by 62.5% assuming full exercise of all warrants sold. The ADSs and warrants will be separately issued, but will be issued and sold in equal proportions.  

Ladenburg Thalmann is acting as lead book-running manager for the proposed offering, subject to customary closing conditions. The number of American Depositary Shares representing Ordinary Shares to be offered, and the price of the American Depositary Shares to be sold in the offering, have not yet been determined. 

The offering of these securities will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained from Vallongatan 1, Telephone: +46 18 50 54 40, Facsimile: +46 18 51 08 73 or by Emailing: [email protected] In addition, the registration statement, including the prospectus, is available to the public at www.sec.gov or www.oasmia.com.  

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.